<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Patel C</submitter><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIGMS NIH HHS</funding><funding>New Jersey Commission on Cancer Research</funding><pagination>103355</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828330</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111</volume><pubmed_abstract>Current chemotherapy regimens have significantly improved overall survival for children with cancer. However, these treatments are associated with detrimental side effects like chemotherapy-induced cognitive impairment (CICI), or "chemobrain." Measurable deficits in cognitive function persist years after treatment. Specifically, doxorubicin (DOXO), a commonly used chemotherapeutic agent in curative regimens for children with cancer, plays a pivotal role in the development of CICI, even though it doesn't cross the blood-brain barrier (BBB). Using a juvenile rat model, we found that DOXO compromises the BBB integrity. To further address the poorly understood mechanism of DOXO-related CICI, we utilized human cerebral microvascular endothelial cells (hCMEC/D3) to study the changes induced by D</pubmed_abstract><journal>Neurotoxicology</journal><pubmed_title>The effects of doxorubicin on blood-brain barrier integrity in hCMEC/D3.</pubmed_title><pmcid>PMC12828330</pmcid><funding_grant_id>R01 CA293210</funding_grant_id><funding_grant_id>T32 GM135141</funding_grant_id><funding_grant_id>COCR24PRF009</funding_grant_id><pubmed_authors>Cole PD</pubmed_authors><pubmed_authors>Patel C</pubmed_authors><pubmed_authors>Glytsou C</pubmed_authors><pubmed_authors>Jang MH</pubmed_authors></additional><is_claimable>false</is_claimable><name>The effects of doxorubicin on blood-brain barrier integrity in hCMEC/D3.</name><description>Current chemotherapy regimens have significantly improved overall survival for children with cancer. However, these treatments are associated with detrimental side effects like chemotherapy-induced cognitive impairment (CICI), or "chemobrain." Measurable deficits in cognitive function persist years after treatment. Specifically, doxorubicin (DOXO), a commonly used chemotherapeutic agent in curative regimens for children with cancer, plays a pivotal role in the development of CICI, even though it doesn't cross the blood-brain barrier (BBB). Using a juvenile rat model, we found that DOXO compromises the BBB integrity. To further address the poorly understood mechanism of DOXO-related CICI, we utilized human cerebral microvascular endothelial cells (hCMEC/D3) to study the changes induced by D</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T22:04:31.763Z</modification><creation>2026-06-05T03:12:15.413Z</creation></dates><accession>S-EPMC12828330</accession><cross_references><pubmed>41265652</pubmed><doi>10.1016/j.neuro.2025.103355</doi></cross_references></HashMap>